Continuous data were described by statistical estimates (mean, standard deviation, median, minimum, and maximum values). An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. It was assumed that all treatment groups present identical baseline virus load at enrolment with a mean value of 5.5 log10 copies/mL3 SD13,14. Guenezan, J. et al. Study endpoints were presented by descriptive statistics, aiming to compare the course of viral load between the three treatment groups. Cite this article. Med. Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19? What scientists say. SARS-CoV-2 viral load predicts COVID-19 mortality. BR, SMS, HS, CA, NW, SA, and RM are employees of ClinCompetence Cologne, the CRO which organized this trial. "CofixRX is an antiviral nasal spray that offers up to 8 hours of protection from many cold and flu viruses." [from your CofixRx Nasal Spray product label] "Lasts for up to 8 hours per. Postdoctoral Fellow Scholarship at Dept of Biochemistry of Vanderbilt University. and B.S. A Boots nasal spray for cold and flu has shown positive results during testing to see if it could help tackle coronavirus infections. ITTintention to treat. Winchester, S., John, S., Jabbar, K. & John, I. Thus, antibody therapy (bamlanivimab and etesevimab) in positively tested, non-hospitalized patients demonstrated that treatment resulted in decreased SARS-CoV-2 viral load by log100.57 on day 11, which was significantly greater compared to placebo (p=0.01)33. Viral load and disease severity in COVID-19. All authors contributed to the preparation of the manuscript, read and approved the manuscript. Elife 10, e69302. The liquid contains NO at 0.11 ppm*hour, which acts as a viricidal agent. Multinomial regression analysis was done to 26 determine the association between nasal carriage of Bacillus and COVID-19 severity after 27 adjusting for age, sex, and co-morbidity status. COVID-19 nasal sprays may one day prevent and treat infection - ABC The team will enrol 480 healthworkers, including nurses and doctors . Emerg. Comparable numbers of adverse events occurred in all treatment groups with no safety concerns. This is exemplified by the emergence of the highly immune evasive omicron variant that is resistant to many monoclonal antibodies authorized for clinical use34. Simon, M. W. The efficacy of azelastine in the prophylaxis of acute upper respiratory tract infections. Absolute changes in viral copy numbers (log10 cp/ml) from baseline (day 1) over time based on the ORF 1a/b gene (Ct<25 analysis set). During visits, nasopharyngeal swabs were taken for quantitative PCR measurements, and investigators assessed the patient status in accordance with the WHO clinical progression scale11. 42, 17. About 388 participants were included in the study Future studies will help understanding the impact of azelastine hydrochloride in treating SARS-CoV-2 infected patients. Early intervention with azelastine nasal spray may reduce viral load in Researchers began to work on compounds that stifle TMPRSS2s ability to interact with the viral protein. Early negativization of SARS-CoV-2 infection by nasal spray of seawater plus additives: The RENAISSANCE open-label controlled clinical trial. J. Ethics approval was granted by the Ethics Committee of the Faculty of Medicine of Cologne University on the 10th of February 2021. Comirnaty is the FDA-approved monovalent COVID-19 (coronavirus 2019) vaccine made by Pfizer for BioNTech. Suitable for 2 and supplementary Table S2). Jean, F. (2022). Inhibition of SARS-CoV-2 by bentonite-based nasal spray. PubMed Central Article FH is the CEO of URSAPHARM Arzneimittel GmbH. Various studies have looked at the role of different foods in preventing coronavirus infection severe Covid-19 These include seaweed and grapefruit-based nasal sprays, dark chocolate, tuna. Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of 90 patients were recruited between 09/03/2021 and 28/04/2021, constituting the safety analysis set. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. All tests were performed two-sided and the type 1 error () was set to 5%. Boots Dual Defence Nasal Spray is used to dampen the symptoms of cold and flu. In addition, presence or absence of fever (38.0C) was documented daily (0=no fever, 3=fever). Chem. During the throes of the COVID-19 pandemic, Anne Moscona didnt feel safe going to a restaurant or catching a flight. Identification of antiviral antihistamines for COVID-19 repurposing. A complete list of inclusion and exclusion criteria is presented in Table 1. The physical and mental health summary scores of the SF-36 questionnaire improved during the course of the treatment without statistical differences between groups (data not shown). https://cornellsun.com/2022/04/27/cornell-research-team-to-develop-covid-19-nose-spray-treatment/, Shapira, T., Monreal, I. Chem. Small differences were found with regard to age and bmi, which were both slightly higher in the azelastine 0.1% group (supplementary Table S1). and F.H. Marinomed plans a clinical trial with Carragelose nasal spray as COVID Our study population was characterized by an initial mean viral load of log10 6.851.31cp/mL, which was higher than more recently reported SARS-CoV-2 viral load values26. De Vries, R. D. et al. reported that a low pH hypromellose nasal powder spray containing common components of nasal sprays could reduce SARS-CoV-2 infection rates19. Article In the meantime, to ensure continued support, we are displaying the site without styles Of note, we cannot rule out the possibility that the placebo (nasal spray buffer) contributed to viral clearance. volume13, Articlenumber:6839 (2023) Expert. Outpatients visiting Corona test centres were informed about the possibility of participating in the trial. Quality of life was assessed with the SF-36 questionnaire as no COVID-19 specific patient-reported outcome measures were available at the time of study. Sin. The study was funded by URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany and CEBINA GmbH Vienna, Austria. The investigators judged the efficacy as good or very good in 74.1% (0.1% azelastine treatment), 82.1% (0.02% azelastine treatment) and 73.1% (placebo treatment) of treated patients. At the end of the study (day 60), all except one single patient (placebo group) showed a score of 0. Because we get infected with SARS-CoV-2 primarily by breathing it in, a nasal spray might be an easy and efficient way to offer protection against the virus, especially in crowded places. was the deputy investigator. Only one of the 20 mice given saline survived. https://doi.org/10.1038/s41591-022-01780-9 (2022). Ghahremanpour, M. M. et al. ADS Comirnaty may help your body develop immunity to SARS-CoV-2, the virus that causes COVID-19. 27, 790792. Boots nasal spray containing seaweed could fight Covid-19 Cornell research team to develop COVID-19 nose spray treatment. Following translocation from nucleus to the endoplasmic reticulum (ER), the sigma-1 receptor (among other factors) plays a role in viral replication. Performance of self-collected saliva testing compared with nasopharyngeal swab testing for the detection of SARS-CoV-2. Cornell Daily Sun. Data on virus variants was available for 59 patients and 54 (92%) of those carried the alpha (B.1.1.7) variant. As a sensitivity analysis based on the SARS-CoV-2 E gene PCR tended to show overall the same effects, PCR results of the E gene are shown in the supplementary material (supplementary Table S3 and S4). Subgroups were analysed exploratorily (e.g., subgroups regarding gender, age, symptom severity, etc.). Google Scholar. The trial medication (placebo nasal spray, 0.02% azelastine nasal spray or 0.1% azelastine nasal spray (the latter being identically composed as the commercial anti-allergic product Pollival) was manufactured at URSAPHARM Arzneimittel GmbH, Saarbruecken, Germany). Pharmacol. Dis. If delivery took place within 24h after sampling, samples were to be stored at<25C, if storage period was greater than 24h (e.g., on Sundays), samples had to be stored and shipped at 28C. Anticipating a drop-out rate of 20%, the aim was to randomize 90 patients in total (30 patients per treatment group) to result in 23 patients per treatment group completing the study and being eligible for analysis. The improvement of the symptom shortness of breath was significantly greater on days 3 (p=0.004) and 4 (p=0.011) in the 0.1% azelastine group compared to placebo (supplementary Figure S3). Investigators assessed patients status throughout the trial including safety follow-ups (days 16 and 60). Sirijatuphat, R., Leelarasamee, A., Puangpet, T. & Thitithanyanont, A. Nature 602, 676681. Approval of the study by the German Federal Institute for Drugs and Medical Devices (BfArM) was given on 3rd February 2021. Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, Ng DC, Biswas S, Zou J, Liu Y, Pandya D, Menachery VD, Rahman S, Cao . We would like to thank Prof. G.A. Both descriptive and exploratory statistics were performed. 10, 294. https://doi.org/10.3389/fphar.2019.00294 (2019). J. Infect. (2021) COVID-19: Azelastine nasal spray reduces virus-load in nasal swabs (CARVIN). Thus, it should be kept in mind that treatment started at a time point where the peak of viral load had probably passed. Article First report on a double-blind placebo-controlled phase II clinical trial. Rev. Components are mixed from two chambers to create the final NO-producing formulation. Antiviral activity was subsequently verified in cell culture. Boots Dual Defence Nasal Spray 20ml - Boots Article At V1, a comparable distribution of patients with a score of 1 (14.8% in the 0.1% azelastine group, 14.3% in the 0.02% azelastine group and 23.1% in the placebo group) or 2 (85.2% in the 0.1% azelastine group, 85.7% in the 0.02% azelastine group and 76.9% in the placebo group) was observed. Studies into Xlear's antiviral effects on SARS . 5) Of note, these differences were not statistically significant (p=0.112). To obtain When treated with N-0385, 70% of the mice survived and had little to no lung damage. Promising nose spray could prevent and treat COVID-19 Kim, M.-C. et al. Inflammopharmacology 29(5), 14. Investigators and trial participants were masked to the treatment as investigational medicinal products were identical in appearance. By submitting a comment you agree to abide by our Terms and Community Guidelines. Other evidence of viral infection showed similar differences between treated and untreated mice in the protective lining of cells called the, inside the nose, nasal mucosa, and airways., : Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants.. Get the most important science stories of the day, free in your inbox. Pharmaceutics 14, 2502. https://doi.org/10.3390/pharmaceutics14112502 (2022). 15, 75297536. Secondary endpoints included the assessment of symptoms, patient status (using a 11-category ordinal score as proposed by the WHO11), body temperature and blood oxygen saturation, quality of life (reported in the SF-36 generic quality of life questionnaires) and safety (adverse events, including worsening of patient status/symptoms) over time. Amdal, C. D. et al. The overall AUC of the Azelastine 0.1% group (red area) was significantly greater than that of placebo (green area), p=0.007. It should be noted that the SARS-CoV-2 alpha variant (B.1.1.7) was the dominant variant in Germany during the enrolment phase of the current study16. A study of frontline workers is looking into how a Boots nasal spray could prevent Covid-19. The Impact of Opioid Use Disorder Services on Overdose Deaths, Access to telehealth and medications for opioid use disorder during the pandemic reduced drug overdose deaths, Bivalent Boosters Offer Better Protection Against Omicron, Updated boosters are more effective at preventing severe COVID-19 from the most common SARS-CoV-2 variant, Page last updated: Struct. Ther. This is similar to the natural SARS-CoV-2 clearance time of approximately 2weeks. Betadine as COVID-19 Prevention Risks - Health Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. 62, 50937, Cologne, Germany, Medical Faculty, Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Kerpener Str. Area under the curve (AUC) reflecting changes in viral copy numbers (log10 cp/mL) from baseline (day 1) over time (until day 11) based on the ORF 1a/b gene (ITT analysis set). C.A. While comparison of categorial variables between groups were performed by Chi square testing, continuous variables were compared using ANCOVA with the factors baseline, visit, and treatment group. Therefore, the primary analysis for the viral loads was conducted non-parametrically. Get the most important science stories of the day, free in your inbox. Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure. Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml Boots Dual Defence Nasal Spray Family Bundle - 4 x 20ml 20.00 Save 3.96 Worth 23.96 when bought separately 1486004 Maximum quantity reached Add to basket Add to favourites Collect 80 Boots Advantage Card points with this purchase Product details In this bundle: Google Scholar. Detection of the alpha (B.1.1.7) variant was based on single nucleotide polymorphism analysis for SARS-CoV-2 spike gene mutation N501Y and deletion H69/V70. 83, 237279. The reduction in virus load over the entire treatment period was clinically meaningful for all three groups (p<0.0001 for both genes). Marc, A. et al. Med. About 388 participants were included in the study PubMed The antiviral also could offer an alternative to people who cannot or do not respond to a vaccine. In a study funded by NIAID, researchers are using mice to look for genes that account for different COVID-19 symptoms. TriSb92 could effectively tip the balance in favor of the [the person] and thereby help to reducethe risk of severe COVID-19 disease, she said.. https://doi.org/10.1089/088318703322751327 (2004). Informed consent was obtained from all participants prior to involvement in the study. COVID-19 Get the latest information from the CDC about COVID-19. JAMA Otolaryngol. Pharmacol. After treatment, virus load was reduced in all groups (p<0.0001) but was greater in the 0.1% group compared to placebo (p=0.007). Many elderly people as well asindividuals who are immunodeficient for various reasons do not respond to vaccines, and are in the need of other protective measures, said Kalle Saksela, MD, PhD, senior author of the study and a virologist at the University of Helsinki. It would be desirable to extend the investigation of azelastine nasal spray as potential antiviral treatment with in vitro culture experiments. Shapira, T., Monreal, I. PubMed Analyses were done on the entire data set (ITT) as well as on a subset population with high viral load defined by baseline Ct values below 25 (Ct<25). Boots nasal spray could help fight COVID-19, new study finds Smell Retraining Therapy - ENT Health Samples of day 1 represent pre-treatment baseline samples. Open Access funding enabled and organized by Projekt DEAL. Researchers have looked for ways to prevent SARS-CoV-2 infection that the virus cant learn to dodge or evade by mutating. Google Scholar. For pairwise comparisons between treatment groups, Mann Whitney U test was performed, and significance levels were adjusted to p<0.0167 based on the Bonferroni correction. Now, researchers at Swansea University will test it against Covid-19. contracts here. In an in vitro screening of 1,800 approved drugs by use of a SARS-CoV-2-S pseudovirus entry inhibitor model, 15 drugs were identified as active inhibitors, but only seven of these drugs were identified as active against SARS-CoV-2, three of which were anti-histamines: clemastine, trimeprazine and azelastine hydrochloride5. Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. Virol. Google Scholar. JAMA 325, 632644. Both have the allure of being variant-proof, Topol added., Many laboratories are shifting from treatments using monoclonal antibodies to treatments using smaller antibody fragments called "nanobodies" because they are more cost-effective and are able to last longer in storage, Mkel and colleagues noted., Several of these nanobodies have shown promise against viruses in cell culture or animal models, including as an intranasal preventive treatment for SARS-CoV-2.. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. PubMed Nature, 10.1038/s41586-022-04661-w. Advance online publication. Three-group comparisons were analysed with KruskalWallis test. 20, e192e197. Biochem. Cegolon, L. et al. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385. Ctcycle threshold. These devices release a low-velocity aerosol mist that can be slowly inhaled over a longer period of time than metered dose and dry powder inhalers. The primary endpoint of the CARVIN study was the assessment of virus load kinetics of SARS-CoV-2 by determining the presence and amount of viral carriage via PCR. Asthma inhalers: Which one's right for you? - Mayo Clinic https://doi.org/10.1056/NEJMc2027040 (2021). The RBD is where the coronavirus attaches to cells in the body. Thus, a nitric oxide nasal spray was shown to reduce the viral load in adult patients with mild COVID-19 infection, and an accelerated SARS-CoV-2 clearance compared to placebo was demonstrated18. Importantly, newly emerging virus variants have the potential to evade the immune response, thereby affecting the efficacy of specific therapies and underlining the importance of new treatment strategies. The product targets a stable site on the spike protein of the virus that is not known to mutate. The efficacy of the treatment was judged as good or very good by 75.0% (0.1% azelastine treatment), 74.1% (0.02% azelastine treatment) and 50.0% (placebo treatment) of patients. Even in cases where the antiviral does not prevent coronavirus infection, the treatment could slow infection. In this context, it is interesting to note that publications indicate that individuals vaccinated against SARS-CoV-2 have lower viral loads and are less contagious24,25. Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail is a medical device innovated to provide the dual-action physical barrier on nasal mucosa that aids the natural defence in which the mucus layer is fortified by a steric barrier-forming agent HPMC and invading viral particles of all major SARS-CoV-2